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Ischemic heart disease after renal transplantation
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until 18 years posttransplant, when he again developed chest
pain. At that time percutaneous angioplasty of a single coro-
nary artery relieved his symptoms.
Throughout his post-transplant course, he had elevated
low-density lipoprotein (LDL) cholesterol (130 mg/dL).
He was prescribed 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors, but he took these irregu-
larly, complaining that they caused bloating and nausea. Fast-
ing triglycerides were generally 200 mg/dL, and the high-
density lipoprotein (HDL) cholesterol was low (35 mg/dL)
on several occasions. Lipoprotein(a) also was elevated (30
mg/dL). He began taking an aspirin, 325 mg daily, after his
first myocardial infarction, and he continued taking aspirin
throughout his posttransplant course. He continued to smoke
11⁄2 packs of cigarettes per day; his fasting blood glucose was
always normal. His blood pressure was well controlled withCASE PRESENTATION
antihypertensive medications that included beta-blockers and
A 33-year-old man received a haplo-identical kidney trans- converting enzyme inhibitors.
plant from his brother in 1979. He had had proteinuria for Twenty years after transplantation he had an acute rise in
16 years prior to transplantation, and his renal disease was serum creatinine, but an allograft biopsy showed only mild
attributed to chronic glomerulonephritis. He had developed chronic allograft nephropathy, and his immunosuppressive reg-
hypertension 10 years before transplantation. He started main- imen (azathioprine and prednisone) was not changed. He de-
tenance hemodialysis 6 months before transplantation, and veloped intermittent atrial fibrillation, which was treated with
after initiating hemodialysis he underwent bilateral nephrec- repeated cardioversion and warfarin. Ultimately, he developed
tomy and splenectomy. In that same month he was hospitalized severe congestive cardiomyopathy, and his name was placed
with chest pain, and a myocardial infarction was ruled out. He on the waiting list for a heart transplant shortly before he died,
had no clinical signs and symptoms of ischemic heart disease 21 years after renal transplantation. Just before he died, his
(IHD); however, he had smoked 11⁄2 packs of cigarettes daily serum creatinine was 1.8 mg/dL, his creatinine clearance was
for approximately 7 years. He was not obese and his physical 53 mL/min, and he had 506 mg/day of protein in his urine.
examination was unremarkable. An electrocardiogram and
chest radiograph were normal.
After transplantation he was treated with azathioprine and DISCUSSION
corticosteroids. He had no acute rejection. Approximately 3
Dr. Bertram L. Kasiske (Director of Nephrology, Hen-months after transplantation he sustained an anteroseptal myo-
nepin County Medical Center, Minneapolis, Minnesota,cardial infarction, documented by cardiac enzyme elevation
and electrocardiographic changes. He continued to have chest USA): This patient illustrates a typical clinical course of
pain, underwent coronary angiography, and had a 3-vessel cor- post-transplant ischemic heart disease (IHD). The only
onary bypass operation 7 months posttransplant. He did well screening for IHD in the pre-transplant evaluation was
until he developed angina pectoris 8 years after transplantation.
a history, physical examination, chest radiograph, andAngiography disclosed occlusions of all 3 bypass grafts and
electrocardiogram, all of which were unremarkable. Nev-diffuse underlying coronary artery disease. He had a 2-vessel
ertheless, it is likely that the myocardial infarction threecoronary artery bypass operation and remained symptom free
months after transplantation resulted from coronary ar-
tery disease already present at the time of transplanta-
The Nephrology Forum is funded in part by grants from Amgen, tion. Throughout the post-transplant course, the patient
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- had recurrent coronary artery disease. Despite the pro-rated; and Bristol-Myers Squibb Company.
gressive nature of this patient’s coronary artery disease
Key words: LDL cholesterol, HDL cholesterol, myocardial infarction. and the less-than-optimal management of risk factors,
aggressive and timely intervention was successful in pre- 2002 by the International Society of Nephrology
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serving his life with a functioning transplant for more tion) are equally safe and effective in renal transplant
recipients. Having established the link between the riskthan 20 years.
The past quarter-century has been a remarkable pe- factor and IHD, and having defined therapy that safely
modifies the risk factor, we must make a “leap of faith”riod for the development of effective immunosuppres-
sive medications in renal transplantation. Current immu- that the reduction in IHD in the general population also
occurs in renal transplant recipients.nosuppression protocols have dramatically reduced the
rate of early acute rejection and have substantially im-
Screening for ischemic heart diseaseproved one-year graft survival rates. Indeed, death with
a functioning allograft now competes with rejection as Pre-transplant IHD is an important risk factor for
post-transplant IHD [2, 3]. In a study at the Universitythe most common cause of “renal allograft failure,” espe-
cially in the late post-transplant period. While the goal of Minnesota, asymptomatic diabetic patients who had
significant coronary artery disease (one or more lesionsof transplantation is to have every patient die with a
functioning kidney transplant, deaths after renal trans- with70% occlusion) were randomly allocated to medical
management or revascularization prior to transplanta-plantation still occur much sooner than those of age-
and gender-matched patients without renal failure [1]. tion. Those who underwent revascularization with either
angioplasty or bypass surgery had significantly fewer IHDDeaths due to infection and malignancies contribute to
this increased mortality rate. However, the leading cause events after transplant surgery [2]. This study suggested
that some high-risk, asymptomatic patients would benefitof death after renal transplantation is cardiovascular dis-
ease. Thus, further improvement in long-term renal allo- from screening and pre-emptive treatment of IHD. Most
transplant centers do not use coronary angiography tograft survival will depend in large part on our ability
to reduce deaths from IHD. Although atherosclerotic screen all high-risk transplant candidates. Angiography
is not only invasive and costly, but it also can acceleratecardiovascular disease (CVD) also causes morbidity and
mortality from cerebral vascular disease and peripheral the patient’s need to initiate dialysis [4]. Most centers
therefore rely on noninvasive cardiac stress testing tovascular disease, the management of risk factors for IHD
will most likely reduce the risk for other atherosclerotic identify asymptomatic patients who need angiography.
The American Society of Transplantation (AST) recom-CVD complications as well.
The last 25 years also have been a remarkable period mends that patients at high-risk, that is, diabetics, older
individuals defined as more than 40 to 45 years of age,for the development of effective strategies for reducing
the morbidity and mortality of IHD. Large, randomized, and individuals with two or more cardiac risk factors,
undergo a cardiac stress test as part of the pre-transplantcontrolled trials in the general population have helped
define the roles of risk-factor intervention with antihyper- evaluation [5]. The role of post-transplant screening for
IHD is poorly defined.tensive medications, lipid-lowering agents, aspirin prophy-
laxis, and other measures in reducing IHD. Of course,
Risk factors for ischemic heart diseasethese trials have excluded patients with renal disease,
and it is unlikely that adequately powered, randomized, Hypertension. The evidence that the pharmacologic
treatment of hypertension effectively reduces both strokecontrolled trials will ever be conducted to confirm the ef-
fectiveness in renal transplant recipients of each of the and IHD in the general population is incontrovertible. In
a meta-analysis published in 1990, Collins and coworkersinterventions already tested in large multicenter trials in
the general population. Therefore, clinicians must decide combined the results from 14 randomized trials that com-
pared the use of diuretics and/or beta-blockers to pla-what evidence can be used to assess which of the thera-
pies effective in the general population should be applied cebo. Over a mean treatment duration of 5 years, they
found a 35% to 40% reduction in stroke and a 20% toto renal transplant recipients.
A reasonable approach might be to first establish that 25% reduction in coronary heart disease [6]. Evidence
from randomized trials such as these led to the devel-the relationship between a particular risk factor and IHD
is similar in the renal transplant population to that in opment of guidelines that recommend treatment of hy-
pertension, with blood pressure thresholds tailored tothe general population. The relationship might not be the
same if, for example, other pathogenetic factors unique to overall IHD risk, using diuretics and beta-blockers as
first-line agents [7]. More recently, interest has shiftedrenal transplant recipients superseded other traditional
risk factors in the development of atherosclerotic IHD. to determining whether newer antihypertensive agents
are as good or better at reducing IHD than diuretics andTherefore, one must establish that traditional, modifi-
able risk factors are independently associated with IHD beta-blockers. A recent meta-analysis of trials comparing
the effect of angiotensin-converting enzyme (ACE) in-events in renal transplant recipients, just as they are in
the general population. Similarly, it is also important to hibitors with placebo reported a 30% reduction in stroke
and a 20% reduction in coronary heart disease despitedetermine that therapies proven to modify these risk fac-
tors (and to reduce the risk of IHD in the general popula- only a 3 mm Hg reduction in systolic blood pressure [8].
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Although this analysis was heavily dependent on a single relatively short follow-up. Thus, although few studies have
documented the relationship between blood pressurelarge trial [9], it suggested that ACE inhibitors have pro-
tective effects that extend beyond blood pressure reduc- and IHD in renal transplant recipients, the data offer no
reason for us to believe that the effect of hypertensiontion, at least in patients selected on the basis of prior
IHD or diabetes. In contrast, the data from randomized on IHD is different in transplant patients compared to
the general population.trials suggest, but do not conclusively prove, that calcium
antagonists increase the risk of IHD compared to diuret- The American Society of Transplantation recommends
routine screening for hypertension and maintenance ofics, beta-blockers, and ACE inhibitors [8, 10]. Altogether,
these recent trials have (1) supported recommendations blood pressure 140/90 mm Hg (but lower if possible)
after renal transplantation [11]. The National Kidney Foun-that diuretics and beta-blockers be used as first-line ther-
apy, (2) suggested a beneficial role for ACE inhibitors dation Task Force on IHD recommends a therapeutic
blood pressure target of 130/85 mm Hg, and 125/75in patients with diabetes or prior IHD, and (3) suggested
that calcium antagonists probably should not be used as mm Hg in patients with proteinuria [18]. Antihyperten-
sive medications generally are safe and effective in renalfirst-line therapy. Ongoing trials comparing antihyper-
tensive agents should help clarify these issues. transplant recipients, and there are no medications for
which there are absolute contraindications. However,Hypertension is common after renal transplantation.
The use of calcineurin inhibitors, cyclosporine A (CsA), some adverse effects of medications are more common in
renal transplant recipients. Diuretics can raise the serumand tacrolimus; the use of corticosteroids; the presence of
native kidneys; and renal allograft dysfunction (including creatinine level in transplant patients. The ACE inhibi-
tors also occasionally raise serum creatinine, but morerenal artery stenosis) all likely contribute to the high
prevalence of post-transplant hypertension. In patients often ACE inhibitors cause mild hyperkalemia, and they
can contribute to anemia. Calcium channel blockers prob-treated with azathioprine and prednisone, the prevalence
of hypertension is 50% to 70% [11]. The prevalence in ably should be used with caution, at least as monotherapy
[16]. Some calcium channel blockers increase blood lev-patients treated with CsA is 65% to 85% [11].
Few studies have examined the relationship between els of cyclosporine. Given the prevalence of IHD, beta-
blockers and ACE inhibitors are particularly attractiveblood pressure and IHD after renal transplantation. How-
ever, in 29,751 transplant recipients in the Collaborative for renal transplant recipients. In the end, more than
half of transplant recipients need combination therapyTransplant Study, hypertension was associated with both
decreased graft and patient survival [12]. Unfortunately, to adequately control blood pressure.
Hyperlipidemia. Randomized controlled trials in theno statistical adjustment was made for renal dysfunction,
and it is certainly plausible that the observed associations general population have provided convincing evidence
that reducing LDL cholesterol effectively decreases thewere due to the fact that graft dysfunction causes hyper-
tension. In a study that included statistical adjustment risk of IHD and lengthens survival. A meta-analysis of
5 randomized trials compared the effects of HMG-CoAfor graft function, blood pressure was an independent pre-
dictor of graft survival in 277 renal transplant recipients reductase inhibitors to placebo in 30,817 patients [19].
Two of the trials included in the meta-analysis were[13]. In another study, hypertension was associated with
graft failure among African Americans but not among primary prevention trials, while three studied patients
with known coronary artery disease. Over a mean dura-whites [14]. However, none of these studies examined
the relationship between blood pressure and IHD per se. tion of 5.4 years of follow-up, treatment was associated
with a 31% (95% confidence interval 26%–36%) reduc-In a recent retrospective, uncontrolled, cross-sectional
study of 287 patients, hypertension was more prevalent tion in the risk of coronary events and a 21% (14%–28%)
reduction in all-cause mortality [19]. The reduction in riskin transplant recipients with coronary artery disease than
in those without CAD [15]. We examined the relation- was similar in men and women, and in those 65 and older
versus those younger than 65 years. Several secondaryship between blood pressure during the first year after
renal transplantation and the subsequent development prevention trials also have shown that nicotinic acid, alone
or in combination with clofibrate or colestipol, reducedof new IHD in a retrospective study of 1124 transplant
recipients [16]. Although the qualitative relationship be- coronary artery disease. Fibrates, for example, gemfibrozil
and bezafibrate, also have reduced coronary artery dis-tween blood pressure and IHD in transplant recipients
was similar to that predicted by the Framingham Heart ease in secondary prevention trials. Because fibrates are
more effective in reducing triglycerides and raising HDLStudy equations [17] (Table 1), the effect of blood pres-
sure was not statistically independent of other risk factors than in reducing LDL, these latter trials have advanced
the debate over the role of therapies targeting triglycerides[16]. Of course, a true effect of blood pressure on coro-
nary artery disease might have been obscured by aggres- and/or low HDL. Ongoing trials are studying whether
reducing triglycerides and raising HDL reduces IHD insive treatment of hypertension, other associated risk fac-
tors such as acute rejection, insufficient sample size, or a patients with normal or only modestly elevated LDL, a
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Table 1. Relative risk for ischemic heart disease in subjects of the Framingham Heart Study versus patients more than
one year after renal transplantationa
Men Women
Variable Framingham Transplant Framingham Transplant
Age, years 1.05 1.06a 1.40 1.10
Age, years2 0.997 0.999
Cholesterol mg/dL
160 0.52 0.00 0.77 0.00
160–199 1.00 1.00 1.00 1.00
200–239 1.19 2.39 1.23 2.07
240–279 1.66 2.02 1.28 2.44
280 1.93 2.25 1.71 1.84
HDL, mg/dL
35 1.64 1.02 2.32 9.16b
35–44 1.28 1.37 1.46 1.48
45–49 1.00 1.00 1.00 0.37
50–59 0.95 1.32 1.00 1.00
60 0.61 1.07 0.65 0.99
Blood pressure, mm Hg
120 and 80 1.00 0.25 0.59 0.56
120–129 or 80–84 1.00 1.00 1.00 1.00
130–139 or 85–89 1.33 1.05 0.93 1.26
140–159 or 90–99 1.68 1.19 1.30 1.63
160 or 100 1.86 1.47 1.59 0.31
Diabetes yes/no 1.53 2.78b 1.82 5.40b
Cigarette use yes/no 1.69 1.95b 1.34 1.82
Reprinted with permission from The American Society of Nephrology [16].
a Shown are relative risks. A relative risk greater or less than 1.00 indicates a higher or lower risk for ischemic heart disease, respectively. For example, among
Framingham Heart Study men, the risk is 5% higher for each one year increase in age. Reference risks for cholesterol, HDL, and blood pressure are indicated by
1.00. Included in the model (but not in the table) were variables testing the effects of missing values (each P  0.2). Abbreviation is HDL, high-density lipoprotein
cholesterol. b P  0.05, P values for Framingham co-efficients are not indicated [17].
lipoprotein profile that is particularly common among found correlations between hyperlipidemia and IHD
after transplantation [3, 35–38]. We recently examineddiabetics. In the meantime, current guidelines emphasize
the importance of reducing LDL, and HMG-CoA reduc- the relationship between lipid levels measured during
the first year after transplantation and the subsequenttase inhibitors are clearly the most effective agents for
reducing LDL cholesterol [20]. development of new IHD in a retrospective study of
1124 transplant recipients [16]. The relationship betweenHyperlipidemia is commonly defined using criteria set
out by the National Cholesterol Education Program total cholesterol, HDL cholesterol, and IHD was similar
in our transplant population compared with that pre-(NCEP) [20]. Low-risk total cholesterol and LDL cho-
lesterol are 200 mg/dL and 130 mg/dL, respectively. dicted by the Framingham Heart Study equations (Ta-
ble 1) [16]. Moreover, cholesterol (and triglycerides)High-risk total cholesterol and LDL are 240 mg/dL
and160 mg/dL. Low HDL is40 mg/dL, and high fast- continued to be independent predictors of IHD even
after multiple risk factors, including acute rejection, wereing triglycerides are200 mg/dL. In the National Kidney
Foundation (NKF) Task Force on Coronary Vascular taken into account (Table 2). Thus, the best current
evidence strongly suggests that hyperlipidemia is associ-Disease (CVD), the prevalence of hyperlipidemia after
renal transplantation was estimated by combining the re- ated with IHD in renal transplant recipients.
The AST Guidelines recommend screening for hyper-sults of studies reporting the proportion of patients with
elevated lipoproteins [21]. In 5 studies, 63% of 549 pa- lipidemia at least once during the first six months and
again at one year after transplantation with fasting totaltients had total cholesterol 240 mg/dL [22–26]. The
LDL cholesterol was130 mg/dL in 60% of 769 patients cholesterol, LDL, HDL, and triglyceride measurements
[11]. Thereafter, annual screening for total cholesterol[22, 27, 28]. In contrast, nearly 90% of 777 patients had
an HDL cholesterol 35 mg/dL [22, 23, 28, 29]. Triglyc- should be carried out in individuals with previously nor-
mal lipid levels and a low risk profile for CVD. Individu-erides were200 mg/dL in 36% of 1309 patients [22, 23,
25, 29–31]. Lipoprotein(a) was30 mg/dL in 23% of 468 als with borderline or previously high lipid levels should
have a complete fasting lipid profile obtained annuallypatients [26, 27, 32–34]. Thus hyperlipidemia, especially
increased LDL, is common after renal transplantation. [11]. The NKF Task Force on CVD recently suggested
that the NCEP Adult Treatment Panel II Guidelines beAlthough few studies have rigorously examined the
relationship between hyperlipidemia and IHD after re- used for the management of hyperlipidemia in patients
with chronic renal disease, including renal transplantnal transplantation, several observational studies have
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Table 2. Risk factors for ischemic heart disease events occurring tion of an HMG-CoA reductase inhibitor to the degree
more than one year after renal transplantation
of LDL elevation. Cheaper, less-potent agents are suitable
Relative for patients with LDL 130–160 mg/dL, because many of
Variable risk 95% C.I. P value these patients will reach target LDL 100 mg/dL. How-
ESRD: type 1 diabetes (0.18) 3.03 1.75–5.24 0.000 ever, more expensive, more potent agents sometimes
ESRD: type 1 diabetes in
are indicated as initial therapy for patients with LDLwomen (0.07) 2.31 1.09–4.86 0.028
ESRD: type 2 diabetes (0.07) 2.79 1.26–6.17 0.012 160 mg/dL (Fig. 1). Comparative studies in the general
ESRD: type 2 diabetes in population have reported the relative potency of dif-
women (0.03) 3.35 0.99–11.3 0.052
ferent HMG-CoA reductase inhibitors. In general, theDiabetes not causing renal
disease (0.04) 2.54 1.15–5.60 0.021 least potent agents are fluvastatin and pravastatin, and
Age (1.00, mean41.8 y) 1.06 1.04–1.08 0.000 the most potent is atorvastatin. Few, if any, HMG-CoA
Age in women
dose-response comparison studies are available in renal(0.44, mean41.5 y) 0.99 0.97–0.99 0.000
Smoking at the time of transplant recipients, treated with or without calcineurin
transplantation (0.25) 1.85 1.23–2.76 0.003 inhibitors.
The management of patients who continue to haveUnderwent transplantation
1986–1992 (0.35) 0.60 0.39–0.92 0.019 LDL100 mg/dL despite treatment with a potent HMG-
Underwent transplantation CoA reductase inhibitor is problematic (Fig. 1). Let me
after 1992 (0.26) 0.27 0.11–0.63 0.002
stress that treatment should not be abandoned, and pa-Two or more first-year
rejections (0.16) 1.62 1.04–2.53 0.034 tients should be encouraged to continue treatment, even
Bilateral nephrectomy (0.29) 0.45 0.26–0.77 0.004 if the target LDL is not reached. Physicians should re-
Bilateral nephrectomy for
mind their patients that the higher the initial LDL cho-PKD (0.04) 3.45 1.50–7.95 0.004
Serum albumin 4.0 g/dL lesterol, the greater the benefit of therapy. Additional
(0.54) 1.71 1.10–2.65 0.017 management options can include changing the immuno-
Proteinuria (0.17) 1.69 1.08–2.64 0.022
suppressive drug and/or adding a second lipid-loweringCholesterol 200 mg/dL
(0.77) 2.18 1.01–4.72 0.048 agent. Each of these options carries some risk, so clini-
Triglycerides 350 mg/dL cians must weigh the relative risk and benefit. In general,
(0.07) 1.90 1.04–3.47 0.038
the higher the LDL and the greater the risk for IHD,
Cox proportional hazards models (N  1124 transplants and 123 IHD events) the more reasonable it becomes to change the immuno-with and without stratifying for renal disease from type 1 diabetes, which violates
the proportional hazards assumption. Shown are relative risks, 95% confidence suppression (if possible) or to add a second lipid-low-
intervals, P values, and (in parentheses) the proportion of patients having the ering agent. For patients treated with CsA, one shouldcharacteristic indicated by that variable. A relative risk greater or less than 1.00
indicates a higher or lower risk for ischemic heart disease, respectively. Included consider substituting tacrolimus for CsA. In randomized
in the models, but not in the table, were variables testing the effects of missing trials comparing tacrolimus to CsA, total and LDL cho-values (each with P  0.5). Abbreviations are ESRD, end-stage renal disease;
PKD, polycystic kidney disease. (Reprinted with permission from The American lesterol were significantly lower in tacrolimus-treated pa-
Society of Nephrology [16].) tients. Moreover, a recent trial randomly allocated CsA-
treated patients with hyperlipidemia to either continue
CsA or switch to tacrolimus. Those who were switched
to tacrolimus had a 25% reduction in LDL cholesterolrecipients [21]. However, the NKF recommends that pa-
tients with chronic renal disease be considered in the compared to those who remained on CsA [39]. Clinicians
also should consider substituting or discontinuing rapa-highest risk category of the classification and treatment
of hyperlipidemia. This approach would mean that trans- mycin in patients who have marked hyperlipidemia. A
more difficult decision is whether to discontinue low-plant recipients should be managed as if they already
had confirmed IHD (Fig. 1). Thus, patients with LDL dose prednisone. Discontinuing prednisone is associated
with an increased risk of acute rejection (10% to 15%). In100 mg/dL should be started on a cholesterol reduction,
Step II American Heart Association diet, with goal LDL addition, although discontinuing prednisone can reduce
total and LDL cholesterol somewhat, it also can reduce100 mg/dL [20]. This diet calls for a saturated fat intake
7% of total calories and cholesterol 200 mg/day. HDL. My own approach is to discontinue CsA in stable
transplant recipients.Patients with LDL130 mg/dL should be treated with
both Step II diet and a lipid-lowering drug, with goal Few studies have examined the safety and efficacy of
combination therapy with lipid-lowering agents in renalLDL 100 mg/dL (Fig. 1) [20]. The drug of choice is an
HMG-CoA reductase inhibitor. However, the dose of the transplant patients. Bile acid sequestrants can be used
effectively in combination with HMG-CoA reductaseHMG-CoA reductase inhibitor should be reduced by 50%
in patients who also are taking a calcineurin inhibitor, inhibitors, but bile acid sequestrants generally should be
avoided in patients with high triglyceride levels. Con-as blood levels of HMG-CoA reductase inhibitors are
increased in patients receiving calcineurin inhibitors. It cerns about reduced bioavailability of CsA have led to
the recommendation that bile acid sequestrants not beis reasonable and most cost-effective to tailor the selec-
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Fig. 1. Treatment of low-density lipoprotein (LDL) cholesterol after renal transplantation. “Low-potency statins” include, for example, fluvastatin
and pravastatin, while atorvastatin is an example of a more expensive “high-potency statin.” Changes in immunosuppression might include: (1)
switching from cyclosporine A to tacrolimus, (2) discontinuing or substituting rapamycin, or (3) reducing or discontinuing prednisone.
administered at the same time as CsA. Fibric acid analogs cessation should be vigorously pursued in renal trans-
plant recipients. Guidelines have been developed forcan be used in combination with HMG-CoA reductase
inhibitors, but the risk of myositis significantly rises with smoking cessation [44, 45].
Glucose intolerance. Epidemiologic studies stronglythis combination, especially in CsA-treated patients. Nic-
otinic acid might be another option. suggest that diabetes greatly increases the risk of IHD
in the general population. In the Framingham HeartCigarette smoking. Of course, no randomized controlled
trials have yet proved that cigarette smoking causes IHD; Study, for example, diabetes increased the risk of coro-
nary heart disease by 53% in men and 82% in womensuch trials would be unethical. Nevertheless, numerous
large, observational studies have shown cigarette smok- (Table 1) [17]. Although it is generally accepted that
diabetes increases the risk of IHD, whether intensiveing to be a major independent risk factor for IHD. In
the Framingham Heart Study, for example, cigarette glycemic control reduces the risk of IHD has been more
difficult to demonstrate. The Diabetes Control and Com-smoking increased the risk of coronary heart disease by
69% in men and 34% in women (Table 1) [17]. plications Trial revealed a (not statistically significant)
tendency for IHD events to be reduced in the intensiveCigarette smoking appears to be as prevalent among
renal transplant recipients as it is in the general popula- glucose control group [46]. In the United Kingdom Pro-
spective Diabetes Study, intensive glycemic control sig-tion [40]. In retrospective, observational studies, ciga-
rette smoking has been linked to IHD [35, 37, 40], early nificantly reduced coronary heart disease events [47].
Thus, current evidence suggests that intensive glycemicmortality [40–42], and graft failure [43]. We found that
the risk associated with cigarette smoking in renal trans- control reduces the incidence of IHD in the general
population.plant recipients with IHD appeared to be greater than
the risk predicted by the Framingham Heart Study. In- A growing number of renal transplant candidates have
renal disease caused by diabetes. In addition, some pa-deed, cigarette smoking increased the risk of a major
IHD event by almost twofold both in men and women tients who do not already have diabetes develop diabetes
after transplantation. Corticosteroids as well as calcineu-(Table 1) [16]. Intervention is often effective, so smoking
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rin inhibitors contribute to the high incidence of post- plantation. Despite a lack of evidence to support their
efficacy in renal transplant recipients, a weight reductiontransplant glucose intolerance. The incidence of new dia-
betes requiring insulin is probably about 5% in the first diet in obese patients and regular exercise in everyone
should be encouraged given the potential for benefit andyear after renal transplantation. The incidence of glucose
intolerance not requiring treatment with insulin has not low risk.
Homocysteine. Several observational studies in thebeen well defined.
Several observational studies demonstrated that dia- general population have linked elevated plasma homo-
cysteine levels to IHD [53, 54]. Results of ongoing ran-betes is a risk factor for IHD after renal transplantation.
The risk of IHD from diabetes is severalfold higher than domized, controlled trials to determine whether lowering
homocysteine reduces the incidence of IHD have not yetthe risk from diabetes predicted by the Framingham
Heart Study equations (Table 1) [16]. It is likely that been reported, however. Thus, it is not known whether
homocysteine plays a pathogenetic role in IHD. Thethe factors important in the pathogenesis of diabetic
nephropathy also are important in the pathogenesis of prevalence of hyperhomocysteinemia is high in renal
transplant recipients compared to the general popula-IHD. Whether new-onset, post-transplant diabetes is also
associated with an increased risk of IHD has not been tion. Moreover, renal transplant patients with IHD have
higher homocysteine levels than do transplant patientsexamined in large, epidemiologic studies. However, post-
transplant diabetes is associated with decreased graft without IHD [55, 56]. Although treatment with folic acid
effectively reduces high homocysteine levels in renalsurvival [48, 49].
Whether intensive glycemic control after renal trans- transplant recipients [57, 58], whether this approach re-
duces IHD will remain uncertain until randomized trialsplantation will help prevent IHD is far from clear. Blood
glucose control is likely to be more difficult to achieve are completed.
Antioxidant vitamins. Studies in the general popula-safely in patients who have long-standing diabetes and
end-organ damage. Autonomic neuropathy causing de- tion have frequently reported an association between
various indicators of oxidized lipoproteins and IHD [59].layed gastric emptying and inability to sense hypogly-
cemia, for example, can make insulin dosing difficult. However, several adequately powered, randomized, pla-
cebo-controlled trials in the general population havePancreas or islet cell transplantation provides optimal
glycemic control and might be a solution for some pa- failed to demonstrate that anti-oxidant vitamins reduce
IHD. Evidence exists for an increased prevalence oftients. Attempts should be made to prevent new-onset
glucose intolerance by minimizing the use of corticoste- small, dense LDL in renal transplant recipients that are
more prone to oxidative modification than are larger,roids and calcineurin inhibitors when possible.
Exercise and weight reduction. Diet and lack of regu- less dense LDL [24]. Evidence also suggests that oxidized
lipoproteins are more common in renal transplant recipi-lar exercise have been linked to IHD in observational
studies in the general population. However, no random- ents than in the general population [24]. However, given
the negative results of randomized trials in the generalized controlled trials have conclusively demonstrated
that a weight-reduction diet or regular exercise program population and the lack of any intervention trials in renal
transplant recipients, treatment with anti-oxidant vita-ameliorates IHD. In meta-analyses of randomized trials
from the general population, single and multiple lifestyle mins does not appear to be warranted.
Aspirin prophylaxis. Studies have shown that low-interventions had modest effects on risk factors, and little
effect on overall or cardiovascular mortality [50, 51]. dose aspirin is effective in preventing recurrent cardio-
vascular events in patients with IHD and/or cerebralGuidelines developed by the National Heart, Lung, and
Blood Institute recommend weight loss to improve lipid vascular disease [60]. A number of guidelines recom-
mend prophylactic aspirin in patients with IHD [60–63].profiles, blood pressure, and glycemic control in patients
with type II diabetes [52]. A low-fat, low-calorie diet is A low dose of aspirin, for example, 65–85 mg, appears
to be as effective as higher doses [60, 64]. Some studiesrecommended along with exercise [52].
Obesity is common after transplantation, in large part indicate that aspirin also is effective in patients without
known CVD [60], but the evidence supporting the usebecause of the use of corticosteroids. Sporadic evidence
also suggests that regular exercise is rare among renal of aspirin in such patients is not as strong. The U.S.
Preventive Services Task Force concluded that there wastransplant recipients. In a retrospective study of 427 renal
transplant recipients, body mass index 25 kg/m2 was evidence neither for nor against the use of aspirin for
primary prevention [65]. The American Diabetes Associ-an independent risk factor for cardiovascular disease
[37]. Otherwise, few data show that obesity or a seden- ation recommended aspirin in patients with diabetes who
have other risk factors for CVD [62]. Because plateletstary lifestyle is an independent risk factor for IHD after
renal transplantation. In addition, few data suggest that from renal transplant patients tend to have increased
aggregability, it seems reasonable to recommend daily,diet or regular exercise is effective in achieving long-term
weight reduction and mitigating IHD after renal trans- low-dose aspirin (65–85 mg/day) for renal transplant pa-
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tients with IHD [66, 67]. Perhaps we should treat other extend beyond their antihypertensive and cholesterol-
lowering properties. Furthermore, both of these familieshigh-risk patients as well; the risk is great enough to
suggest that all renal transplant patients receive aspirin of drugs are renoprotective. Could you please comment
on the merits of adopting a relatively liberal policy forprophylaxis unless it is contra-indicated. My own ap-
proach is to use low-dose aspirin in all renal transplant using these medications in renal transplant recipients?
Dr. Kasiske: That is a very good point. A lot of datarecipients, unless it is contraindicated.
Infections and inflammation. Recent evidence suggests from studies in the general population indicate that ACE
inhibitors and HMG-CoA reductase inhibitors have ben-that IHD is a systemic disease characterized by inflam-
mation. Systemic inflammatory markers such as C-reac- eficial effects on endothelial function. We like these drugs
for these and other reasons, not just because they reducetive protein and fibrinogen have been correlated with
IHD events. One of the reasons that aspirin has been blood pressure and LDL cholesterol. In addition, up to
one-fourth of our transplant population eventually de-effective in reducing IHD in patients with pre-existing
cardiovascular disease might be its anti-inflammatory velops persistent proteinuria, for example, over 500 mg/
24 h, and some of these patients become nephrotic. Dataproperties. However, few randomized controlled trials
testing the efficacy of antimicrobial therapies in reducing suggest that we can reduce proteinuria using ACE inhibi-
tors in renal transplant recipients. On the other hand, IIHD have been completed to date [68]. In renal trans-
plant recipients, IHD has been associated with low serum know that some transplant centers are reluctant to use
ACE inhibitors, because of the fear of provoking analbumin, which also might be a marker of systemic in-
flammation [16]. Until additional randomized controlled increase in serum creatinine. We don’t feel that way, but
we do watch serum creatinine closely after starting antrials are completed, it will be difficult to translate this
and other observations supporting the role of infection ACE inhibitor. We also reduce the dose of HMG-CoA
reductase inhibitors by about 50% in patients who areand systemic inflammation in IHD into useful interven-
receiving cyclosporine A or tacrolimus because of thetion strategies.
well-known interaction between these agents.
Summary Dr. Madias: Left ventricular hypertrophy (LVH) is
an independent risk factor for CVD. Do you have infor-Dramatic improvements in renal allograft survival
mation on the magnitude of its role in renal transplantover the last 10 years have shifted the focus of post-
recipients and recommendations for its diagnosis andtransplant management from short-term considerations
management? Also, could you comment on the recentlyto reduction of deaths due to IHD (and other causes)
reported association between coronary artery calcifica-over the long term. A growing body of evidence suggests
tions, as detected by electron beam computed tomogra-that the high incidence of IHD after renal transplanta-
phy, and the increased elemental calcium intake in youngtion is in large part due to the high prevalence of tradi-
adult patients treated with dialysis [69]? It could repre-tional risk factors such as hypertension and hyperlipid-
sent yet another nontraditional risk factor for IHD inemia. It is neither feasible nor necessary to demonstrate
ESRD patients and renal transplant recipients.that treating risk factors like elevated blood pressure
Dr. Kasiske: Unfortunately, we do not have good dataand LDL cholesterol is justified in reducing morbidity
on LVH in our transplant population. We know thatand mortality from IHD. Recent data suggest that the
LVH often improves after transplantation, and there areincidence of IHD is declining in some centers [16], likely
a number of reasons for this. Before the introductionbecause of the use of new medications that effectively
of erythropoietin, anemia was common in hemodialysisreduce factors for IHD. Further emphasis on managing
patients. Correcting anemia with transplantation no doubtthese risk factors, along with additional studies to iden-
decreased the incidence and severity of LVH in at leasttify new prevention strategies, are needed if progress in
some studies from that era. Volume overload also canreducing this major cause of death in transplant patients
masquerade as LVH, and volume status can improve af-is to continue.
ter transplantation. Whether other “uremic” factors can
be improved with transplantation, and thereby cause a re-
QUESTIONS AND ANSWERS gression of LVH, is still debated. As you pointed out,
Dr. Nicolaos E. Madias (Executive Academic Dean, electron beam tomography studies show a high incidence
Tufts University School of Medicine, Boston, Massachu- of coronary artery calcification in hemodialysis patients
setts, USA): Endothelial dysfunction caused by immuno- [69]. Of course, maintaining normal calcium and phos-
suppressive agents might be one of the nontraditional phorus levels in hemodialysis patients is always a chal-
risk factors that contribute to IHD after renal trans- lenge. In contrast, stable renal transplant recipients
plantation. As you know, ACE inhibitors and HMG- usually have normal calcium and phosphorus levels.
CoA reductase inhibitors defend the structural and func- Whether the incidence of coronary artery calcification
after transplantation declines is unknown. Of course, thetional integrity of the vasculature via mechanisms that
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clinical significance of coronary calcifications is also not unclear. Perhaps systemic inflammation plays an impor-
tant role, for example, inflammation from the dialysisknown. They could contribute to the pathogenesis of
coronary lesions or they could be an epiphenomenon of membrane, infections, or other factors. Whether a high
calcium-phosphorus product is important, and whetherlittle functional significance.
Dr. Hamid Rabb (Hennepin County Medical Center, we might help reduce the incidence of CVD by avoiding
calcium-containing phosphate binders are both impor-University of Minnesota School of Medicine, Minneapo-
lis, Minnesota): Recent evidence has implicated inflam- tant questions without answers at this time.
Dr. Madias: How much information do we have re-mation in the pathogenesis of atherosclerotic CVD. In
fact, data indicate that T-cells themselves could be major garding the incidence of CVD in relatively comparable
populations of dialysis and transplant patients? Do wemediators of ischemic reperfusion injury and potentiate
myocardial infarction. Activation of T-cells directed at have any good data on CVD in waiting list patients?
Dr. Kasiske: Robert Wolfe and coworkers comparedthe allograft, as we see in our transplant patients, could
prime T-cells to promiscuously damage the myocardium. the overall mortality of transplant recipients with those
still on the waiting list [70]. Mortality was higher for pa-Is there any known link between T-cells and IHD after
transplantation? tients on the transplant waiting list compared to trans-
plant recipients. Of course, the assumption was made thatDr. Kasiske: I am not aware of any studies addressing
this directly, but it is a very interesting hypothesis. In- everyone who was on the waiting list was a transplant
candidate. Unfortunately, no data corroborate this as-deed, the general hypothesis that systemic inflammation
plays an important role in the pathogenesis of atheroscle- sumption, and it is likely that an unknown proportion
of waiting list patients were “on hold.” Nevertheless, therotic CVD is a fascinating one. Unfortunately, almost
all the data supporting it are circumstantial. However, I difference in mortality between waiting list and trans-
plant patients was very large, and it is therefore unlikelybelieve that it is a very plausible hypothesis, and perhaps
mechanisms like those you are suggesting could be im- to be artifactual. Although not addressed in this study, it
is likely that much of the difference in mortality betweenportant. We have noted that low serum albumin after
transplantation is associated with subsequent IHD events. these two populations is due to a difference in CVD
events. At the American Society of Nephrology meetingIt is possible that hypoalbuminemia acts as a marker of
systemic inflammation, similar to elevations in C-reactive in Toronto, October 13–16, 2000, we presented a prelimi-
nary analysis demonstrating that the incidence of CVDprotein. On the other hand, we failed to find a statistically
significant association between CMV infections and IHD is indeed higher among patients on the waiting list com-
pared to transplant recipients. It is remarkable that de-in our transplant population. Nevertheless, the idea that
a chronic inflammatory state, for example, from infec- spite the very high prevalence of CVD risk factors after
transplantation, transplant recipients still seem to havetions or subclinical rejection, primes T-cell involvement
is a very good one. a lower incidence of CVD relative to comparable dialysis
patients. That really suggests to me that there is some-Dr. Mark Rosenberg (University of Minnesota School
of Medicine): As you know, we do not do a good job of thing going on in the dialysis population that is very bad
with respect to CVD.controlling risk factors in our dialysis patients. Dialysis
and transplant patients have a very high risk of CVD, Dr. Charles A. Herzog (Cardiology Division, Hen-
nepin County Medical Center, University of Minnesotaand we might even be doing things to make that worse,
such as calcium supplementation. How much of the bur- School of Medicine, and Director of the Cardiovascular
Special Studies Center, United States Renal Data System,den of posttransplant CVD is present at the time of
transplantation? Isn’t one of the best things we can do Minneapolis): Dr. Manske’s study is the only random-
ized, controlled trial examining the effects of pre-trans-to prevent posttransplant CVD preventing pre-trans-
plant CVD? plant screening and prophylactic intervention on out-
comes [2]. The study suggested that revascularization ofDr. Kasiske: Certainly CVD is present in a large num-
ber of patients at the time of transplantation. However, asymptomatic diabetic patients with significant coronary
artery stenosis reduced the number of cardiac eventsin the Kaplan-Meier curve showing the accumulation of
IHD events after transplantation [3], it is apparent that compared to medical management. If this result is true,
it provides a strong argument for screening as part of thethe risk for new events is still accruing even 15 to 20
years after transplantation. It is unlikely that these late pre-transplant evaluation. Unfortunately, the number of
patients in the study was very small. In addition, optimalevents are due to pre-transplant IHD. It is more plausible
that CVD is acquired both before and after transplanta- medical management has changed since the time of the
study; if the study were done today, a beta-blocker mighttion. Your point is valid, and certainly risk factor man-
agement before transplantation in the dialysis popula- be selected instead of a calcium antagonist, for example.
It is also unfortunate that revascularization included bothtion is important. However, the factors that cause a very
high incidence of CVD in the dialysis population are still bypass surgery and angioplasty, procedures that might
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have very different success rates in this population. Where conscious of risk factors and are adopting healthier life-
should we go from here? styles. In addition, we have better antihypertensive medi-
Dr. Kasiske: I believe that a large-scale, randomized, cations and better lipid-lowering agents, and we have
controlled trial is warranted to examine outcomes after been using these aggressively in our transplant popula-
screening versus no screening in a population of high- tion. The other thing that appears to have changed over
risk patients. Screening could be done with a noninvasive the years, at least in our institution, is the level of aware-
stress test followed by angiography and revascularization ness of IHD and the aggressiveness of screening and
as indicated by defined criteria. Appropriate inclusion intervention. We have been doing a lot more screening
and exclusion criteria could be specified to avoid includ- for IHD, and we have been doing a lot more intervention
ing patients in whom such screening is necessary. Such a with bypass surgery, angioplasty, and stent placement.
study also would need to address the issue of re-screening All of these could contribute to the reduced incidence
while patients are on the waiting list. Of course, the study of IHD events. In terms of screening after transplanta-
would have to be designed in such a way that costs were tion, that is also something we have discussed a lot lately.
not prohibitive. Should screening go beyond just the pre-transplant
Dr. Michael Aaronson (Nephrology Fellow, Univer- workup? Certainly patients with known IHD periodi-
sity of Minnesota Division of Nephrology): The patient in cally receive a noninvasive cardiac stress test. Perhaps
the case had an elevated lipoprotein(a), an inflammation we should also be screening all high-risk patients after
marker. Given the current paradigm of inflammation as transplantation.
a possible risk factor for IHD, if a transplant patient has Dr. Horacio Esteban Adrogue´ (Medicine and Pedi-
a normal serum creatinine, is it unreasonable to prescribe atrics Resident, University of Minnesota School of Medi-
an anti-inflammatory medication in an attempt to decrease cine): What, if any, role do elevated levels of homo-
IHD? Also, if this patient had nephrotic-range protein- cysteine play in the renal transplant patient as an inde-
uria, would it have been reasonable to use nonsteroidal pendent risk factor for IHD? Are high levels considered
anti-inflammatory drugs to reduce the proteinuria? as high a risk factor as in dialysis patients? How is this
Dr. Kasiske: These are both very good questions. Is managed?
the reduction in IHD from prophylactic aspirin seen in Dr. Kasiske: We know that homocysteine correlates
randomized trials in the general population due not only with IHD after transplantation. We also know that one can
to the antiplatelet effect of aspirin but also to an anti- lower homocysteine levels with a combination of vita-
inflammatory effect? If there were a higher inflammatory mins B6, B12, and folate. Unfortunately, we are still wait-state after renal transplantation, for whatever reasons, ing for the results of randomized trials that demonstrate
would anti-inflammatory medications be beneficial? Un-
lowering homocysteine reduces IHD events. One could
fortunately, no clinical trial data answer this question.
argue that taking vitamins is innocuous, so that we shouldObviously, the problem with using nonsteroidal anti-
be doing this even without good data from clinical trials.inflammatory medications is the potential for adverse
On the other hand, transplant patients already take mul-effects, for example, an increase in serum creatinine, in-
tiple medications, and adding more pills would increaseterstitial nephritis, gastrointestinal bleeding. Currently,
the risk of noncompliance. I would hate to see a trans-we recommend the use of low-dose, prophylactic aspirin,
plant patient miss doses of immunosuppressive medica-for example, approximately 80 mg/day, in transplant re-
tions because we complicated the drug regimen by add-cipients at risk for CVD. When we have patients with
ing a number of medications of unproven benefit.persistent proteinuria (1 g/24 h), we first try using an
Dr. Madias: Should the recommendations that youACE inhibitor to control the proteinuria, and we gener-
made, at least the relevant ones, be amended for pediat-ally avoid using nonsteroidal anti-inflammatory agents
ric transplantation?in this setting.
Dr. Kasiske: I do not know. Cardiovascular risk fac-Dr. Madias: Could you please expand on the most
tors have only recently received the attention of pediatricplausible reasons for the declining incidence of IHD ob-
nephrologists. With improved outcomes after renal trans-served in some centers? Also, could you comment on
plantation in the pediatric age group, more of these pa-the role of screening for IHD after transplantation?
tients are surviving into adulthood. It is plausible thatDr. Kasiske: It is very heartening to see that the inci-
we will see more IHD in young adults who have had adence of IHD has been declining in our transplant popu-
transplant for an extended period. So I think there is alation. It would be nice to know why this is so, but we
growing need for risk factor management in the pediatriccan only speculate. Of course, the incidence has been
age group. Unfortunately there are not a lot of data infalling in the general population, and the reduction has
this area.been attributed to both better risk factor management
Dr. Aaronson: Is the rate of IHD different in patientsand better screening and treatment of IHD in the general
population. Perhaps our transplant recipients are more who have received a kidney transplant versus a kidney/
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pancreas transplant? Is the kidney/pancreas transplant levels of low-density lipoprotein cholesterol. The advan-
tage of this approach would be to avoid the commoncardioprotective?
Dr. Kasiske: The problem that we have with under- problem of undertreatment. I think that would be a rea-
sonable approach, one worth considering.standing the benefits of pancreas transplantation is that
there have never been any randomized controlled trials. Dr. Madias: If I recall correctly, in your analysis, bilat-
eral nephrectomy for PKD increased the risk for IHD,Any arguments about the effects of pancreas transplan-
tation on microvascular or macrovascular disease are highly but the same procedure for non-PKD patients was asso-
ciated with decreased risk. Could you please commentspeculative. Pancreas transplant recipients are highly se-
lected patients. I do not think you can adequately adjust on this issue?
Dr. Kasiske: Having a bilateral nephrectomy beforefor this fact statistically by using multivariate analysis. I
think the question is impossible to answer in the absence transplantation, a practice that was more common 20
years ago, was associated with less IHD. This might resultof clinical trials. Unfortunately, the obstacles to conduct-
ing such a trial might be insurmountable. from better blood pressure control. However, when we
looked for interactions in the analysis, we found thatDr. Madias: You mentioned some data indicating an
inverse relationship between blood pressure in renal patients who had polycystic kidney disease and under-
went bilateral nephrectomy had an increased risk oftransplant recipients and graft survival. Did this relation-
ship feature a threshold value below which no benefit IHD. I suspect that many of those polycystic kidney
disease patients had bilateral nephrectomy because theyon survival could be discerned? Also, were any classes of
antihypertensive medications associated with increased had very large kidneys. Polycystic kidney disease by itself
was not a risk factor for IHD; it was only a risk factorbenefit?
Dr. Kasiske: The Collaborative Transplant Study reg- among patients who had bilateral nephrectomy. In analy-
ses such as this, the possibility always exists that one oristry appears to show a simple linear relationship be-
tween blood pressure and graft failure [71]. There is no more of the several risk factors were statistically signifi-
cant only by chance. However, there is an independentJ-shaped curve, and one cannot see a threshold effect of
blood pressure on patient or graft survival. Few data on study that also reported that patients with polycystic
kidney disease have an increased risk of IHD after trans-the relative merits of different antihypertensive agents
in renal transplant recipients are available, and certainly plantation [72]. This makes it more likely that ours was
not a chance finding.no data from large, randomized controlled trials that
have measured outcomes in this population. In our re- Dr. Rosenberg: How much can we reduce the CVD
burden by selecting immunosuppressive agents with min-cent observational study of risk factors for IHD, we
found that patients who were taking dihydropyridine imal adverse effects on CVD risk factors? I was struck
by a recent article looking at cyclosporine A versus ta-calcium antagonists one year after transplantation were
at increased risk for subsequent IHD events [16]. No crolimus that showed that both blood pressure and lipids
were decreased with tacrolimus [73]. The other issue isother antihypertensive medication was associated with
IHD. This was a retrospective analysis, and there could whether steroid avoidance can decrease cardiovascular
risk factors.be several reasons for this association. For example, the
patients who were already at high risk for IHD might Dr. Kasiske: Unfortunately, most of the studies exam-
ining the effects of changes in immunosuppression onhave been more likely to be treated with dihydropyridine
calcium antagonists. Nevertheless, the fact that other CVD risk have only followed patients over a relatively
short period and have only measured one or two cardio-studies in the general population have raised concerns
about calcium antagonists and IHD makes this result vascular risk factors. While it might not be feasible to
conduct trials to examine the incidence of CVD eventsdisconcerting.
Dr. Shakeel Anjum (Nephrology Fellow, University for all different combinations of immunosuppression, it
is nevertheless important to at least examine the effectsof Minnesota Division of Nephrology): Considering that
renal transplant patients are at high risk to begin with, of changes in immunosuppression on all of the well-
established CVD risk factors over a sufficiently long pe-and that they will be on immunosuppression after trans-
plantation, would it be reasonable to give everyone a riod by intention-to-treat analysis. For example, it might
be easy to show that after prednisone withdrawal, thestatin after transplantation?
Dr. Kasiske: The prevalence of hyperlipidemia and serum cholesterol goes down and blood pressure im-
proves. However, what you also have to factor into thethe risk for IHD are so high that one can make an
argument that every patient should be started on an CVD risk equation is the percentage of patients who
have an acute rejection. In those patients, graft dysfunc-HMG-CoA reductase inhibitor as part of the initial im-
munosuppression protocol, or at least at the time of tion or the higher doses of steroids required to treat
rejection can adversely affect CVD risk. Perhaps thehospital discharge after transplantation. The agent then
could be stopped if the recipient subsequently had low best approach is to randomize patients to different immu-
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in insulin-dependent diabetic patients with chronic renal failure.nosuppression strategies, measure all the known CVD
Lancet 340:998–1002, 1992
risk factors over a follow-up period of at least several 3. Kasiske BL, Guijarro C, Massy ZA, et al: Cardiovascular disease
months, and then calculate the expected CVD risk based after renal transplantation. J Am Soc Nephrol 7:158–165, 1996
4. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropa-on validated equations such as the Framingham Heart
thy in azotemic diabetic patients undergoing coronary angiography.
Study equations. This approach might be a reasonable Am J Med 89:615–620, 1990
surrogate for cardiovascular events when it is not possi- 5. Kasiske BL, Ramos EL, Gaston RS, et al: The evaluation of
renal transplant candidates: Clinical practice guidelines. J Am Socble to follow enough patients over a long enough period
Nephrol 6:1–34, 1995to examine the effects of immunosuppression on actual 6. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke,
CVD events. and coronary heart disease. Part 2, short-term reductions in blood
pressure: Overview of randomised drug trials in their epidemiologi-Dr. Madias: Also, you have to factor in the difference
cal context. Lancet 335:827–838, 1990in the incidence of new diabetes. 7. The Sixth Report of the Joint National Committee on Prevention,
Dr. Kasiske: I agree. In addition to their effects on Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med 157:2413–2446, 1997dyslipidemia and blood pressure, several immunosup-
8. Neal B, MacMahon S, Chapman N: Blood Pressure Loweringpressive agents, such as corticosteroids, cyclosporine A, Treatment Trialists’ Collaboration: Effects of ACE inhibitors, cal-
and sirolimus, contribute to the high incidence of post- cium antagonists, and other blood-pressure-lowering drugs: Re-
sults of prospectively designed overviews of randomised trials.transplant diabetes.
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